Immunogen (IMGN) Misses Q2 EPS by 3c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/21/2026
- Wall St futures gain as chip stocks extend recovery; earnings in focus
- Oil prices rise nearly 2% on fresh attacks by US and Iran
- Chip stocks extend global rebound following last week's rout
- Adobe, Salesforce and Intuit fall as Morgan Stanley begins cautious coverage
- Danaher shares tumble despite earnings beat
- U.S. to impose 50% tariff on most Canadian goods, including USMCA
- NVIDIA reports 9.3% passive stake in Nebius
- Wall Street indexes fall, with Iran and earnings season in focus
- Cantor Fitzgerald Starts Trulieve Cannabis (TRLV) at Overweight, 'Purpose-Built for a New Cannabis Regulatory Framework'
- Selloff of U.S. memory stocks creates a compelling entry point: analyst
ImmunoGen Reports Recent Progress and Second Quarter 2022 Financial Results
July 29, 2022 6:30 AM EDTBLA for Mirvetuximab Soravtansine Monotherapy in Ovarian Cancer Accepted by FDA with Priority Review; PDUFA Date Set for November 28, 2022
Completed enrollment in the Confirmatory MIRASOL Study
Presented Additional Efficacy and Safety Data for Mirvetuximab Monotherapy at ASCO; Poster Highlighting Updated SORAYA Data Selected for Best of ASCO® Program
Announced Multi-Year Collaboration with Oxford BioTherapeutics to Research and Develop Novel ADCs
Conference Call to be Held at 8:00 a.m. ET Today
WALTHAM, Mass.--(BUSINESS... More
